Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-year randomized, open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplantation.

Next Previous
Trial Profile

A 3-year randomized, open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplantation.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Corticosteroids
  • Indications Bronchiolitis obliterans; Lung transplant rejection
  • Focus Therapeutic Use
  • Acronyms CeMyLung

    • Most Recent Events

    • 23 Aug 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 21 Apr 2012 3-year results presented at the 32nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 30 Apr 2011 Planned number of patients changed from 240 to 320.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top